参考文献
［1］He Y,Liang D,Li D,et al.Incidence and mortality of laryngeal cancer in China,2015［J］.Chin J Cancer Res,2020,32(1):10-17.
［2］Sinicrope FA,Shi Q,Allegra CJ,et al.Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage Ⅲ Colon Cancers:A Secondary Analysis of 2 Randomized Clinical Trials［J］.JAMA Oncol,2017,3(4):472-480.
［3］Grothey A,Van Cutsem E,Sobrero A,et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT):an international,multicentre,randomised,placebocontrolled,phase 3 trial［J］.Lancet,2013,381(9863):303-312.
［4］Kopetz S,Grothey A,Yaeger R,et al.Encorafenib,Binimetinib,and Cetuximab in BRAF V600E-Mutated Colorectal Cancer［J］.N Engl J Med,2019,381(17):1632-1643.
［5］Corcoran RB,André T,Atreya CE,et al.Combined BRAF,EGFR,and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer［J］.Cancer Discov,2018,8(4):428-443.
［6］Cleary JM,Wang V,Heist RS,et al.Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors［J］.Clin Cancer Res,2021,27(11):2996-3004.
［7］Innocenti F,Ou FS,Qu X,et al.Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome［J］.J Clin Oncol,2019,37(14):1217-1227.
［8］Saltz LB,Clarke S,Díaz-Rubio E,et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase Ⅲ study［J］.J Clin Oncol,2008,26(12):2013-2019.
［9］Cunningham D,Lang I,Marcuello E,et al.Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer(AVEX):an open-label,randomised phase 3 trial［J］.Lancet Oncol,2013,14(11):1077-1085.
［10］Kopetz S,Guthrie KA,Morris VK,et al.Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer(SWOG S1406)［J］.J Clin Oncol,2021,39(4):285-294.
［11］Tan J,Liu R,Zhu G,et al.TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors:Achilles Heel［J］.Proc Natl Acad Sci U S A,2020,117(27):15846-15851.
［12］Grothey A,Fakih M,Tabernero J.Management of BRAF-mutant metastatic colorectal cancer:a review of treatment options and evidence-based guidelines［J］.Ann Oncol,2021,32(8):959-967.
［13］Sahin IH,Goyal S,Pumpalova Y,et al.Mismatch Repair(MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer［J］.Oncologist,2021,26(8):668-675.
［14］Meric-Bernstam F,Hurwitz H,Raghav K,et al.Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway):an updated report from a multicentre,open-label,phase 2a,multiple basket study［J］.Lancet Oncol,2019,20(4):518-530.
［15］Belli V,Matrone N,Napolitano S,et al.Combined blockade of MEK and PI3KCA as aneffective antitumor strategy in HER2 gene amplified human colorectal cancer models［J］.J Exp Clin Cancer Res,2019,38(1):236.
［16］Kanat O,Ertas H,Caner B.Dual HER2 inhibition strategies in the management of treatmentrefractory metastatic colorectal cancer:History and status［J］.World J Clin Cases,2018,6(11):418-425.
［17］Bregni G,Sciallero S,Sobrero A.HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer［J］.JAMA Oncol,2019,5(5):605-606.
［18］Feng Y,Li Y,Huang D,et al.HER2 as a potential biomarker guiding adjuvant chemotherapy in stage Ⅱ colorectal cancer［J］.Eur J Surg Oncol,2019,45(2):167-173.
［19］Tan R,Camat MD,Ng M,et al.HER2 positive rates are enriched amongst colorectal cancer brain metastases:a study amongst 1920 consecutive patients［J］.Ann Oncol,2018,29(7):1598-1599.
［20］Hyman DM,Piha-Paul SA,Won H,et al.HER kinase inhibition in patients with HER2- and HER3-mutant cancers［J］.Nature,2018,554(7691):189-194.(https://www.daowen.com)
［21］Kavuri SM,Jain N,Galimi F,et al.HER2 activating mutations are targets for colorectal cancer treatment［J］.Cancer Discov,2015,5(8):832-841.
［22］Sartore-Bianchi A,Trusolino L,Martino C,et al.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory,KRAS codon 12/13 wild-type,HER2-positive metastatic colorectal cancer(HERACLES):a proof-of-concept,multicentre,open-label,phase 2 trial［J］.Lancet Oncol,2016,17(6):738-746.
［23］Buhmeida A,Assidi M,Al-Maghrabi J,et al.Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma:Evaluation of Prognostic Value Using Both IHC & BDISH［J］.Cancer Invest,2018,36(2):129-140.
［24］Hainsworth JD,Meric-Bernstam F,Swanton C,et al.Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles:Results From MyPathway,an Open-Label,Phase IIa Multiple Basket Study［J］.J Clin Oncol,2018,36(6):536-542.
［25］Sawada K,Nakamura Y,Yamanaka T,et al.Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer［J］.Clin Colorectal Cancer,2018,17(3):198-205.
［26］Qiu MZ,He CY,Yang XH,et al.Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma［J］.Oncologist,2021,26(7):e1161-e1170.
［27］Fakih MG.Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer［J］.Oncologist,2018,23(4):474-477.
［28］Siena S,Sartore-Bianchi A,Marsoni S,et al.Targeting the human epidermal growth factor receptor 2(HER2) oncogene in colorectal cancer［J］.Ann Oncol,2018,29(5):1108-1119.
［29］Takegawa N,Yonesaka K.HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy［J］.Clin Colorectal Cancer,2017,16(4):247-251.
［30］Delattre JF,Cohen R,Henriques J,et al.Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage Ⅲ Colon Cancer:A Post Hoc Analysis of the IDEA France Phase Ⅲ Trial(PRODIGE-GERCOR)［J］.J Clin Oncol,2020,38(15):1702-1710.
［31］Xu RH,Muro K,Morita S,et al.Modified XELIRI(capecitabine plus irinotecan) versus FOLFIRI(leucovorin,fluorouracil,and irinotecan),both either with or without bevacizumab,as second-line therapy for metastatic colorectal cancer(AXEPT):a multicentre,open-label,randomised,non-inferiority,phase 3 trial［J］.Lancet Oncol,2018,19(5):660-671.
［32］Van Cutsem E,Cervantes A,Adam R,et al.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer［J］.Ann Oncol,2016,27(8):1386-1422.
［33］Pelly VS,Moeini A,Roelofsen LM,et al.Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy［J］.Cancer Discov,2021,11(10):2602-2619.
［34］Hu H,Kang L,Zhang J,et al.Neoadjuvant PD-1 blockade with toripalimab,with or without celecoxib,in mismatch repair-deficient or microsatellite instability-high,locally advanced,colorectal cancer(PICC):a single-centre,parallel-group,non-comparative,randomised,phase 2 trial［J］.Lancet Gastroenterol Hepatol,2022,7(1):38-48.
［35］Kanikarla Marie P,Haymaker C,Parra ER,et al.Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases［J］.Clin Cancer Res,2021,27(11):3039-3049.
［36］Limagne E,Thibaudin M,Nuttin L,et al.Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages［J］.Cancer Immunol Res,2019,7(12):1958-1969.
［37］Cousin S,Cantarel C,Guegan JP,et al.Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer(REGOMUNE):A Single-arm,Open-label,Phase II Trial［J］.Clin Cancer Res,2021,27(8):2139-2147.
［38］Chalabi M,Fanchi LF,Dijkstra KK,et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers［J］.Nat Med,2020,26(4):566-576.
［39］Martinelli E,Ciardiello D,Martini G,et al.Implementing anti-epidermal growth factor receptor(EGFR) therapy in metastatic colorectal cancer:challenges and future perspectives［J］.Ann Oncol,2020,31(1):30-40.
［40］Ganesh K,Stadler ZK,Cercek A,et al.Immunotherapy in colorectal cancer:rationale,challenges and potential［J］.Nat Rev Gastroenterol Hepatol,2019,16(6):361-375.